



Clinical Oncology Findings from Seattle Cancer Care Alliance (SCCA) Clinicians to be Featured at the 2021 ASCO Annual Meeting

Seattle, Wash. (June 3, 2021) -- Seattle Cancer Care Alliance (SCCA) announced today the list of presentations from the organization's clinicians that will be presented at the [2021 American Society of Clinical Oncology \(ASCO\) Annual Meeting](#) from June 4-8, 2021. SCCA clinicians contributed to studies across multiple cancer types addressing the full continuum of cancer care – from prevention to diagnosis to treatment. Presentations will highlight results from trials in Phase 1, CAR T-cell therapy, breast cancer, bladder cancer, non-small cell lung cancer and hematologic cancers. Additionally, there are multiple studies on the impact of the COVID-19 pandemic on cancer diagnosis, clinical care and oncology clinical trials. SCCA clinical researchers also contributed to new findings related to genetic profiling, prostate needle biopsy pathology and precision therapy for salivary gland cancer.

"SCCA is a leader in groundbreaking clinical trials turning scientific discovery into exciting new treatments that often change the way cancer care is delivered," said Nancy Davidson, MD, president and executive director of Seattle Cancer Care Alliance and a former ASCO president. "The work being presented by our physician-researchers at ASCO 2021 further demonstrates these continued efforts to improve the way patients are treated and advance multidisciplinary cancer care."

More information about SCCA's presentations and publications at ASCO is available at: <https://www.seattlecca.org/conference/asco-2021>

Presentation Details:

[Breast cancer screening for carriers of ATM, CHEK2, and PALB2 pathogenic variants: A comparative modeling analysis.](#)

Abstract: 10500

SCCA author: [Kathryn P. Lowry, MD](#)

[Impact of disruptions in breast cancer control due to the COVID-19 pandemic on breast cancer mortality in the United States: Estimates from collaborative simulation modeling.](#)

Abstract: 6562

SCCA author: [Kathryn P. Lowry, MD](#)

[Phase I study of adoptive immunotherapy for advanced MUC1* positive breast cancer with autologous T cells engineered to express a chimeric antigen receptor, huMNC2-CAR44 specific for a cleaved form of MUC1 \(MUC1*\).](#)

Abstract: TPS2663

SCCA author: [Jennifer M. Specht, MD](#) and [David G. Maloney, MD, PhD](#)

[Efficacy of enobosarm, a selective androgen receptor \(AR\) targeting agent, correlates with the degree of AR positivity in advanced AR+/estrogen receptor \(ER\)+ breast cancer in an international phase 2 clinical study.](#)

Abstract: 1020

SCCA author: [Hannah M. Linden, MD](#)

[AMEERA-1: Phase 1/2 study of amcenestrant \(SAR439859\), an oral selective estrogen receptor \(ER\) degrader \(SERD\), with palbociclib \(palbo\) in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative \(HER2-\) metastatic breast cancer \(mBC\).](#)

Abstract: 1058

SCCA author: [Hannah M. Linden, MD](#)

Case-Based Panel: Optimizing Precision Therapy in Salivary Gland Cancers With a Look at the Future

SCCA speaker: [Cristina P. Rodriguez, MD](#)

PrE0807: A phase Ib feasibility trial of neoadjuvant nivolumab (N) without or with lirilumab (L) in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC).

Abstract: 4518

SCCA author: [Petros Grivas, MD, PhD](#)

[Avelumab first-line \(1L\) maintenance plus best supportive care \(BSC\) versus BSC alone for advanced urothelial carcinoma \(UC\): Analysis of time to end of next-line therapy in JAVELIN Bladder 100.](#)

Abstract: 4525

SCCA author: [Petros Grivas, MD, PhD](#)

[The fluciclovine \(FACBC\) PET/CT site-directed therapy of oligometastatic prostate cancer \(Flu-BLAST-PC\) trial.](#)

Abstract: TPS5099

SCCA author: Risa L. Wong, [Jonathan L. Wright, MD, MS](#), [Heather H. Cheng, MD, PhD](#) and [Evan Y. Yu, MD](#)

[Clinical accuracy of information extracted from prostate needle biopsy pathology reports using natural language processing.](#)

Abstract: 1557

SCCA author: Risa L. Wong and [John L. Gore, MD, MS, FACS](#)

[Clinically advanced pelvic squamous cell carcinomas \(pSCC\) in men and women: A comprehensive genomic profiling \(CGP\) study.](#)

Abstract: 3130

SCCA author: [Petros Grivas, MD, PhD](#)

[Concordance of DNA damage repair \(DDR\) gene mutations in paired primary and metastatic prostate cancer \(PC\) samples.](#)

Abstract: 5020

SCCA author: [Michael T. Schweizer, MD](#), [Evan Y. Yu, MD](#) and [Colin C. Pritchard, MD, PhD](#)

[Case Based Panel: Optimizing Urothelial Cancer Management From Organ-Confined to Metastatic Disease: A Multidisciplinary Approach](#)

SCCA Moderator/Chair: [Evan Y. Yu, MD](#)

[Oral Session: Germline Genetic Testing for Prostate Cancer](#)

SCCA Discussant: [Colin C. Pritchard, MD, PhD](#)

[CD19 CAR T-cell product type independently impacts CRS and ICANS severity in patients with aggressive NHL.](#)

Abstract: 7532

SCCA author: [Jordan Gauthier, MD, MSc](#), [Mazyar Shadman, MD, MPH](#), [David G. Maloney, MD, PhD](#) and [Cameron J. Turtle, MBBS, PhD, FRACP, FRCPA](#)

[Efficacy of clinical breast examination in chest-irradiated female survivors of childhood Hodgkin lymphoma \(HL\).](#)

Abstract: 10028

SCCA author: [Janie M. Lee, MD, MSc](#)

[Demographics, outcomes, and risk factors for patients \(Pts\) with sarcoma and COVID-19: A multi-institutional cohort analysis.](#)

Abstract: 11523

SCCA author: [Michael J. Wagner, MD](#)

[Avelumab in patients with previously treated Merkel cell carcinoma \(JAVELIN Merkel 200\): Updated overall survival data after more than five years of follow up.](#)

Abstract: 9517

SCCA author: [Paul Nghiem, MD, PhD](#)

[Efficacy and safety of patritumab deruxtecan \(HER3-DXd\) in EGFR inhibitor-resistant, EGFR-mutated \(EGFRm\) non-small cell lung cancer \(NSCLC\).](#)

Abstract: 9007

SCCA author: [Christina S. Baik, MD, MPH](#)

[Oral Session: Emerging Trends in Radiation for Localized Lung Cancers](#)

SCCA discussant: [Ramesh Rengan, MD, PhD](#)

[Phase 1b dose escalation study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of GS-3583, a FLT3 agonist Fc fusion protein, in patients with advanced solid tumors.](#)

Abstract: TPS3147

SCCA author: [John A. Thompson, MD](#)

[First-in-human phase I/II study of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination in patients with advanced solid and hematologic cancers.](#)

Abstract: 3006

SCCA author: [Ryan C. Lynch, MD](#)

Education Session: COG Perspective on the Impact of COVID-19 on Pediatric Oncology Clinical Trials and Implications for the Future

SCCA speaker: [Douglas S. Hawkins, MD](#)

[Poster Discussion Session: COVID-19 and Cancer: Learning As We Go Along](#)

SCCA discussant: [Petros Grivas, MD, PhD](#)

[Cancer diagnosis and adverse financial events: Evidence from credit reports.](#)

Abstract: 6504

SCCA author: [Veena Shankaran, MD, MS](#)

[Choosing Wisely: Selecting the Right Population at the Right Time for DNA-Damaging Therapy](#)

SCCA discussant: [Elizabeth M. Swisher, MD](#)

About Seattle Cancer Care Alliance

Seattle Cancer Care Alliance brings together the leading research teams and cancer specialists from Fred Hutch, Seattle Children's and UW Medicine — one extraordinary group whose sole purpose is the pursuit of better, longer, richer lives for our patients. Based in Seattle's South Lake Union neighborhood, Seattle Cancer Care Alliance has nine clinical care sites in the region, including a medical oncology clinic at EvergreenHealth in Kirkland; hematology/medical oncology and infusion services at Overlake Medical Center in Bellevue, medical and radiation oncology clinics at UW Medical Center - Northwest Seattle and medical oncology services at SCCA Issaquah, as well as Network affiliations with hospitals in five states. For more information about SCCA, visit seattlecca.org.

Contacts

Karina San Juan, ksanjuangu@seattlecca.org or (206) 640-4782

Heather Platisha, hplatisha@seattlecca.org or (415) 676-8030